Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma.
The findings, which suggest that the approach has the potential to be effective against tumours that have already spread to other parts of the body and against different cancer types, were reported in Nature Nanotechnology.
Cancer cells employ strategies to switch off various stages of the cancer-immunity cycle, the process by which dendritic cells educate T cells to kill cancer cells. This immunosuppressive environment that impedes activation of cancer-killing T cells allows tumours to grow, according to the researchers.
“Most approaches to boost this critical role of dendritic cells aim to increase the activation signals provided to dendritic cells when specific molecules on their surface bind to tumour cells. However, these have not been as successful in clinical trials as hoped. This is because tumours have a tendency to evolve in different ways to switch off each stage of the cancer-immunity cycle,” said Yizhou Dong, corresponding author of the study, Professor of Oncological Sciences, and a member of the Icahn Genomics Institute and the Marc and Jennifer Lipschultz Precision Immunology Institute at Icahn Mount Sinai.
The researchers named their approach CATCH. As part of the regimen, the researchers used new types of lipid nanoparticles to deliver two mRNA therapeutics.
Using multiple bioassays to gain insights on the effects of the CATCH regimen on different types of immune cells, the researchers showed that their strategy not only reactivated the cycle but also removed obstacles at other stages.
Potential in a range of solid tumours
Beyond the positive findings in mouse models of melanoma, the researchers conducted further tests to evaluate the effectiveness of the CATCH regimen in restarting the cancer immunity cycle more broadly.
Their investigations revealed encouraging results, as the regimen reduced tumours in mouse models of B cell lymphoma by 83%. They also tested it in mouse models of breast cancer, where approximately half of the mice favourably responded. Next, the researchers plan to start early-phase clinical trials for patients.
“Dendritic cells have been a key focus for the development of new cancer therapies as these cells organise the cancer-immunity cycle. In theory, the CATCH regimen using this particular RNA-based technology has the potential to provide a much more effective approach for using dendritic cells for cancer immunotherapy to treat a wide range of solid tumours,” said Brian Brown, Director of the Icahn Genomics Institute and Associate Director of the Marc and Jennifer Lipschultz Precision Immunology Institute at Icahn Mount Sinai.
